Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,847
  • Shares Outstanding, K 30,338
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,640 K
  • EBIT $ -24 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.83

Options Overview Details

View History
  • Implied Volatility 312.07% ( -65.45%)
  • Historical Volatility 78.44%
  • IV Percentile 92%
  • IV Rank 80.66%
  • IV High 384.96% on 10/08/24
  • IV Low 8.06% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 380
  • Open Int (30-Day) 451

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.34
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.23 +1.16%
on 11/20/24
5.96 -28.19%
on 11/08/24
-0.35 (-7.56%)
since 10/18/24
3-Month
2.95 +45.08%
on 09/20/24
7.47 -42.70%
on 08/27/24
-0.98 (-18.63%)
since 08/20/24
52-Week
1.44 +197.22%
on 12/01/23
19.41 -77.95%
on 03/04/24
+2.59 (+152.88%)
since 11/20/23

Most Recent Stories

More News
Insider Sale: Chief Development Officer of $SKYE (SKYE) Sells 19,489 Shares

Tuan Tu Diep, the Chief Development Officer of $SKYE ($SKYE), sold 19,489 shares of the company on 11-18-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 19.2%...

SKYE : 4.28 (-1.38%)
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

SKYE : 4.28 (-1.38%)
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

SKYE : 4.28 (-1.38%)
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

SKYE : 4.28 (-1.38%)
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

SKYE : 4.28 (-1.38%)
Skye Bioscience to Announce Third Quarter 2024 Results

SKYE : 4.28 (-1.38%)
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

SKYE : 4.28 (-1.38%)
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

SKYE : 4.28 (-1.38%)
MarketBeat Week in Review – 10/7 - 10/11

Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings

NFLX : 883.85 (+1.44%)
NVDA : 145.89 (-0.76%)
META : 565.52 (+0.79%)
AAPL : 229.00 (+0.32%)
SKYE : 4.28 (-1.38%)
XOM : 120.32 (+1.42%)
NU : 13.32 (-1.04%)
CCL : 25.08 (-0.20%)
DAL : 63.64 (-1.71%)
WMT : 87.18 (+0.67%)
PLTR : 62.12 (-1.37%)
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

SKYE : 4.28 (-1.38%)
NVO : 105.27 (+2.57%)
LLY : 753.41 (+3.25%)

Business Summary

Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.

See More

Key Turning Points

3rd Resistance Point 4.80
2nd Resistance Point 4.67
1st Resistance Point 4.48
Last Price 4.28
1st Support Level 4.16
2nd Support Level 4.03
3rd Support Level 3.84

See More

52-Week High 19.41
Fibonacci 61.8% 12.55
Fibonacci 50% 10.42
Fibonacci 38.2% 8.30
Last Price 4.28
52-Week Low 1.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar